Clareo Health | Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Wyeth is now a wholly owned subsidiary of Pfizer
Age
20–74
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
CD22-positive, B-cell NHL which has progressed after 1 or 2 prior therapies.
Patients who have progressed after at least 1 prior chemotherapy regimen for indolent lymphoma, or 1/ 2 chemotherapy regimens, which include anthracylin or anthraquinon for aggressive lymphoma.
Eastern Cooperative Oncology Group (ECOG) performance status: 0/ 1.
You may not be if
Patients must not have received monoclonal antibodies or radioimmunoconjugates within 3 months before first dose of test article.
Patients must not have received bilateral pelvic irradiation.
Patients must not have received chemotherapy, cancer immunosuppressive therapy, growth factors (except erythropoietin), or investigational agents within 4 weeks before first dose of test article.
